Fazeshift looks to streamline and automate manual processes with AI agents

SAN FRANCISCO, Jan. 7, 2025 — Fazeshift, an AI agent for Accounts Receivable, raised $4M in seed funding led by Gradient, Google’s early-stage AI fund. The round also included investment from Y Combinator, Wayfinder, Pioneer Fund, Ritual Capital, Phoenix Fund, and prominent angels including Terrence Rohan, Kulveer Taggar, and Rich Aberman.

Enterprises waste over $200 billion annually managing accounts receivable (AR), bogged down by manual tasks like reconciling payments, generating invoices, and chasing overdue accounts. Fazeshift streamlines this process by automating everything from invoice creation to payment reconciliation, freeing teams from hours of manual work.

Unlike traditional robotic process automation (RPA), which struggles to understand the nuances of AR, Fazeshift’s LLM-powered approach handles complex workflows with ease. Fazeshift’s use of highly specialized LLM prompts tuned to each specific task, allows it to achieve the accuracy and flexibility required for enterprise-grade operations.

“We are seeing AI agents that can reason, perform human-like tasks, and do so with the nuance required for these more sensitive business applications. Eventually we’re going to see all tedious and manual back-office tasks be eliminated. The opportunity for transformation in AR is massive, and this funding allows us to accelerate our product development and customer acquisition efforts,” said Caitlin Leksana, CEO and Co-Founder of Fazeshift.

Fazeshift’s AI agents don’t just answer questions – they can handle complex billing workflows, send customer emails, and even update accounting records. They do this by manipulating the same software tools that human teams previously used. Fazeshift has proven that AI agents can penetrate even the most sensitive business processes.

“The B2B payments stack is being completely reinvented since AI agents have become more mainstream. Finance teams at companies large and small typically struggle with monthly reconciliation and collecting overdue invoices. These finance processes are typically manual and tedious,” said Darian Shirazi, Managing Partner at Gradient. “We’re excited to partner with the Fazeshift team as they streamline finance processes while still giving significant customization and visibility to finance operations teams.”

Fazeshift is already working with several large enterprise customers and automating workflows that previously required teams of 12 people. As the AR space becomes increasingly complex, Fazeshift is positioning itself as the go-to solution for enterprises looking to streamline their AR process.

About Fazeshift
Fazeshift is an AI agent for Accounts Receivable. With Fazeshift, companies can automate their entire accounts receivable process across their existing tools, helping them save time and money, while improving cash flow. Fazeshift is backed by leading investors including Y Combinator and Gradient, Google’s early-stage AI fund. For more information, visit https://fazeshift.com.

About Gradient
Gradient has been investing at the forefront of artificial intelligence since 2017. We are led by former founders, technical experts, and domain specialists who have supported hundreds of AI founders from the beginning. Gradient is headquartered in San Francisco. For more information, visit www.gradient.com.

SOURCE Fazeshift

Revolutionizing AI-Driven Peptide Therapeutics, Strengthening Pipeline for Next-Generation Drug Discovery

JERUSALEM, Jan. 7, 2025 — Pepticom, a pioneer in AI-driven peptide-based therapeutics, today announced the successful completion of its Series A1 funding round, securing $6.6 million. Japan Israel High Tech Ventures 2 LP led the round, with strong participation from existing investors.

This funding will accelerate the development of Pepticom’s oral IL-17 inhibitor program, targeting improved treatments for autoimmune diseases. This includes the design of two families of fully synthetic, small cyclic peptidomimetic inhibitors with nanomolar activity that target both IL-17A and IL-17F isoforms. Composed of non-natural amino acids, these compounds have achieved key milestones in record time and cost, demonstrating increased stability and extended half-life in vitro and in vivo.

By addressing unmet needs in psoriasis, psoriatic arthritis and other autoimmune diseases, Pepticom’s AI-driven drug discovery platform is advancing next-generation therapeutics to overcome limitations of traditional small molecule and biologic therapies in complex therapeutic areas.

Pepticom’s proprietary platform for de novo design, and discovery of peptide therapeutics, combines state-of-the-art machine learning with cutting-edge biochemistry to design peptides with exceptional specificity, stability, and therapeutic potential.

By combining over 600 natural and non-natural amino acid building blocks with AI-driven reinforcement learning, Pepticom can explore an infinite chemical space—over 10⁸⁰ potential peptide structures. This enables the de novo design and discovery of entirely new peptidomimetic targets that provides significant advantages over other therapeutic modalities. This unique capability accelerates the drug discovery process, bringing us closer to impactful peptide therapies in a fraction of the time and cost compared to traditional methods.

“This successful funding round validates our pioneering approach to AI-driven peptide drug discovery,” said Immanuel Lerner, CEO and Co-Founder of Pepticom. “Our platform’s design of novel oral IL-17 inhibitors in record time and cost demonstrates its transformative impact to redefine how precision peptide therapeutics are discovered and developed. This funding accelerates our mission to bring more effective, accessible treatments to patients across multiple therapeutic areas.” 

About Pepticom: Pepticom is a biotech company specializing in the AI-driven discovery of peptide-based therapeutics. The company’s mission is to transform medicine by developing targeted, more effective treatments for serious diseases, including autoimmune disorders, and other high-need therapeutic areas. By harnessing the unique properties of peptides, Pepticom’s innovative approach creates precision therapies that address complex biological challenges, offering a new frontier in drug development. For more information, visit: www.Pepticom.com.

About Japan Israel High Tech Ventures 2 LP:

Japan Israel High Tech Ventures 2 LP, a venture capital fund established in 2022, is managed by Singapore-based Chartered Investment Managers Pte. Ltd. The fund specializes in investing in Israeli and Israeli-affiliated technology companies. To date, it has backed 19 Israeli startups across diverse deep-tech sectors, as well as one university-affiliated venture capital initiative in Israel.

A Message from the Chairman of Chartered Group:

“This investment marks a pivotal milestone in our commitment to fostering groundbreaking technologies that address critical challenges in healthcare. Pepticom’s pioneering approach to AI-driven peptide therapeutics aligns seamlessly with our vision of supporting transformative innovations with the potential to revolutionize lives globally. We are proud to contribute to Pepticom’s journey in developing next-generation therapies that not only address unmet medical needs but also set new standards for efficiency and precision in drug discovery,” said Eyal Agmoni, Chairman of Chartered Group.

www.pepticom.com

SOURCE Pepticom

Capital and resources will further drive product innovation and grow the company’s global customer base

BOSTON, Jan. 7, 2025 — Northern Light Group, the leading enterprise knowledge management platform for competitive intelligence and market research, today announced a $23 million growth investment by LoneTree, a New York-based growth capital firm. The investment will accelerate Northern Light’s ability to scale, providing capital and resources to drive continued product innovation and enhance its ability to support enterprise customers worldwide.

With a customer base that includes many of the world’s largest pharmaceutical, technology, financial services, consumer products, manufacturing and healthcare companies, Northern Light has built a loyal following of research-driven organizations that require enterprise-wide access to information. These organizations depend on Northern Light’s intelligence and research for successful strategy, R&D, product management, marketing and sales.

“In a world where enterprises rely on massive data sets across multiple first and third-party systems to shape their growth and product strategies, it is imperative for organizations to effectively manage their content and data to maximize insights potential and create a more knowledgeable and efficient workforce,” said Mike Devine, Partner at LoneTree. “Northern Light has emerged as a leader through consistently working to understand each customer’s unique needs, and providing transformative solutions. It has a phenomenal team and an exceptional company culture, and we are looking forward to supporting them in the next chapter of their growth and evolution.”

“Over the past two decades, Northern Light has prioritized customer satisfaction and continuous innovation as a means of building the market’s most comprehensive enterprise-focused competitive intelligence and market research offering,” said David Seuss, CEO of Northern Light. “The investment by LoneTree is a significant milestone, validating our current and future market position and product strength. We are well-positioned to drive innovation, deliver exceptional value to our customers and foster new career growth opportunities for our employees.”

Seuss added, “We chose LoneTree as a partner because of the firm’s sector expertise, collaborative investment approach and experience with helping companies accelerate their growth. Together, we will continue to innovate and better meet the evolving needs of our customers.”

As part of the investment, Mike Devine, Rhett Lambert and Peter Bozian will join Northern Light’s Board of Directors. Terms of the deal were not disclosed. Goulston & Storrs PC provided legal counsel to Northern Light. Goodwin Procter LLP represented LoneTree.

About Northern Light

Northern Light provides knowledge management platforms for competitive intelligence and market research insights to global enterprises across multiple industries, including information technology, pharmaceuticals, telecommunications and financial services. It has more than 200,000 users of its strategic research portals worldwide and has repeatedly been recognized by industry analysts and journalists as one of the companies empowering intelligent knowledge management. Visit https://northernlight.com.

About LoneTree Capital 

Founded in 2021 and headquartered in New York City, LoneTree provides operational and M&A support alongside flexible capital to accelerate revenue growth. The firm enables partner companies—notably, founder-owned bootstrapped businesses, divisions of larger enterprises and formerly venture-backed companies—to achieve their next stage of growth quicker and with a higher level of certainty. For more information on LoneTree, please visit www.lonetreecap.com. 

Media contact:
David Domeshek
Northern Light
(508) 873-7068
[email protected]

SOURCE Northern Light

The round led by NewSpring will fuel continued growth as the company releases GenAI Agents that leverage proprietary insurance data

NEW YORK, Jan. 7, 2025 — Jones, the vertical software company leading AI innovation in insurance verification, today announced the close of its $15M Series B funding round led by NewSpring Capital, a growth equity firm managing $3.5 billion in capital with over 250 platform investments, via its dedicated growth and expansion strategy, NewSpring Growth. The round also saw continued participation from major existing investors, including Hetz Ventures, Camber Creek, Khosla Ventures, JLL Spark, DivcoWest Ventures, Rudin Ventures, and Ground Up Ventures.

Founded by Omri Stern and Michael Rudman, Jones is an AI-driven vertical software company that helps real estate and construction clients to accelerate the collection of insurance certificates (COIs), endorsements, and policies, verify compliance with precision, and integrate bi-directionally with key ERP systems. The company has scaled to 25,039 real estate properties and construction projects across over 2.5 billion square feet in the United States.

The investment marks a pivotal moment for Jones as it doubles down on its mission to help clients make smart decisions about insurance risk so they can boost efficiency and mitigate insurance claims. Jones plans to release a suite of AI-powered Agents, smart assistants that automate routine tasks, reduce manual workloads, and offer autonomous decision-making. The AI Agents are fine-tuned by proprietary data including insurance logic, risk benchmarks, and millions of verified insurance documents. The company also plans to continue expanding software workflows and deepening ERP integrations.

“COI and insurance policy verification is a highly manual and error-prone process, making it ripe for disruption through automation,” said Marc Lederman, General Partner at NewSpring Capital. “Jones AI solutions enable construction and real estate companies to scale their departments efficiently while mitigating legal and financial risks in today’s highly litigious environment. As compliance becomes more complex and regulatory demands rise, Jones has ample room for continued expansion and represents exactly the type of growth-oriented business we seek for investment.”

With this funding, Jones is focused on addressing the ballooning insurance costs in the industry. The company’s latest release, Insurance Policy Verification, helps clients to flag and interpret exclusionary language in insurance policies to mitigate costly payouts from third-party insurance claims, a problem plaguing the industry that COIs do not solve. “The insurance markets have been reeling from economic pressures and are one of the biggest challenges facing real estate and construction, whether it’s from headwinds in origination or the lack of digitization,” said Omri Stern, CEO of Jones. “We’re excited to be part of a cohort of maturing growth-stage AI and data companies that are partnering with the insurance industry to help clients make smarter decisions about insurance risk.”

The Series B funding highlights the company’s success in addressing one of the toughest challenges in the category: scaling an AI-driven software solution in an industry heavily reliant on human-in-the-loop processes. Jones resolved the manual bottleneck by combining machine learning with human compliance experts, paving the way for unparalleled efficiency and scalability. This milestone signals the confidence of investors in the company’s ability to continue building a category-defining business model.

About Jones

Jones is an AI-driven software company helping real estate and construction firms to make smart decisions about insurance risk so they can boost efficiency and mitigate insurance claims. In over 2 billion square feet of real estate and construction projects, Jones helps clients to accelerate and fortify their insurance verification, collection, integration, and decisioning across both commercial or residential asset classes. To learn more, visit www.getjones.com.

About NewSpring

NewSpring partners with the innovators, makers, and operators of high-performing companies in dynamic industries to catalyze new growth and seize compelling opportunities. The Firm manages over $3.5 billion across five distinct strategies covering the spectrum from growth equity and control buyouts to mezzanine debt. Having completed over 250 investments, NewSpring brings a wealth of knowledge, experience, and resources to take growing companies to the next level and beyond. Partnering with management teams to help develop their businesses into market leaders, NewSpring identifies opportunities and builds relationships using its network of industry leaders and influencers across a wide array of operational areas and industries. To learn more, visit www.newspringcapital.com.

SOURCE Jones

NEW YORK, Jan. 7, 2025 — Waterpoint Lane (“the Firm”) is proud to announce the successful final close of its inaugural fund, Waterpoint Lane Sustainability Fund I (“Fund I”), marking a defining moment in its evolution as a leading impact investment manager. Fund I has attracted strong support from a distinguished global investor base, including premier family offices and high-net-worth individuals, all united by a commitment to advancing impact and innovation within the global food system.

Founded in 2021 as a specialized SPV investor, Waterpoint Lane has rapidly evolved into a full-scale investment manager. The successful close of Fund I underscores this transformation and reinforces the firm’s disciplined approach to identifying and scaling cutting-edge technologies that drive sustainable productivity across the agrifood value chain.

Fund I will focus on growth-stage B2B companies leveraging breakthrough technology to solve critical challenges in food and agriculture, with a clear emphasis on enhancing efficiency, sustainability, and resilience. The fund has already made several strategic investments and is actively building a robust pipeline of transformative opportunities.

Ben Gibbons, Founder and Co-Managing Partner of Waterpoint Lane, shared:
“We are deeply honored by the trust our limited partners have placed in us. This successful fundraise validates the strength of our investment thesis and our shared belief in the power of innovation to catalyze meaningful change in the global food system.”

Meifan Shi, Co-Managing Partner, stated:
“With Fund I, we’re building more than a portfolio—we’re crafting a blueprint for scalable, impact-driven value creation. By supporting visionary entrepreneurs and deploying bold strategies, we aim to set new benchmarks for innovation and leadership in this critical sector. Fund I represents a pivotal step in positioning Waterpoint Lane as a transformative force in sustainable investing.”

Waterpoint Lane’s investment strategy integrates capital with strategic growth initiatives, leveraging deep sector expertise and an extensive global network. The firm is uniquely positioned to deliver both financial returns and measurable impact, aligning the interests of its investors, portfolio companies, and the broader communities it serves.

About Waterpoint Lane
Waterpoint Lane is a leading venture capital firm dedicated to advancing productivity and sustainability in the global food system. Since its founding in 2021, the firm has grown from a single-purpose vehicle into a full-scale investment manager, combining disciplined strategies with a mission-driven approach to impact. By partnering with visionary entrepreneurs, Waterpoint Lane addresses critical challenges, redefines industry standards, and unlocks new opportunities for growth and innovation.

For more information, please visit www.waterpointlane.com

Media Contact
For inquiries, please reach out to:
Investor Relations
[email protected]
www.waterpointlane.com

SOURCE Waterpoint Lane

The investment will enable TONCASH to accelerate the onboarding of millions of users to its innovative crypto cashback platform and build the Web3 standard for best-price shopping.

HONG KONG, Jan. 7, 2025 — TONCASH, the Telegram-native crypto cashback and rewards platform, has received a strategic investment from TON Ventures, the flagship venture fund of The Open Network (TON). The strategic investment will accelerate TONCASH’s mission to onboard millions of users and become the Web3 standard for best-price shopping and on-chain rewards.

Ben Usinger, CEO and Co-Founder of TONCASH, commented: “This investment deepens our collaboration with Telegram and The Open Network, empowering us to deliver the best online shopping and rewards experience for the Web3 audience. With TON Ventures’ strategic support, we’re driving the adoption of on-chain payments, engaging millions of users through innovative cashback mechanics and redefining how brands connect with customers in the Web3 space.”

Since launching its Telegram Mini App in November 2024, TONCASH has gained over 200,000 users and a large following on social media, underscoring its product-market fit and rapid growth potential.

TONCASH users enjoy deals from over 200 top brands, including Apple, Adidas, Binance, or Trip.com, offering up to 80% cashback — redeemable in Bitcoin, USDT, or TON tokens. Beyond cashback, the mini app provides perks such as airdrops and engagement rewards, all while operating seamlessly on any phone with Telegram installed.

With TON Ventures’ backing, TONCASH now pursues an aggressive expansion across Asia-Pacific, Europe, the Middle East, and Latin America, reaching Telegram’s 950-million-user base and connecting global brands to Web3 users through crypto cashback and rewards.

To join the app and benefit from its perks:

Visit: TONCASH website

Join us on Telegram

SOURCE TONCASH

The funding will advance Senseera’s GEM BIOMARKERS™ liquid biopsy platform, powered by cfChIP-seq technology. The platform decodes cell-specific gene expression and cell states from a simple blood draw, providing detailed molecular insights for diagnosing and monitoring diseases. This transformative approach delivers the precision of biopsy-level insights with the convenience of a non-invasive blood test.

Senseera’s technology is built on decades of research led by Prof. Nir Friedman and validated in top-tier journals such as Nature Biotechnology. Supported by data from over 20,000 human samples, Senseera has established a robust foundation for accelerating drug development and precision medicine in oncology, immunology, and metabolic diseases, and revolutionizing liver diseases management. Liver diseases represent a significant global health challenge, affecting up to 25% of the population. Existing diagnostics often rely on invasive and risky biopsies or non-specific tests, resulting in delayed diagnoses and suboptimal patient care. Senseera’s platform offers an innovative solution for early detection and management of conditions like MASLD/MASH, liver transplant rejection, and hepatocellular carcinoma (HCC). The funds will accelerate market entry of Senseera’s next generation transplant rejection test, advance clinical trials, and expand partnerships with global biopharma.

In addition to its unique liver diseases diagnostics pipeline, Senseera’s platform offers unparalleled potential for accelerating drug development in cancer and immune disorders. By providing simultaneous solid tissue and immune cell states monitoring, the platform provides insights into tissue/tumor immune cross-talk, enabling researchers and clinicians to better understand the underlying mechanisms and support personalized treatments.

“This funding marks a major milestone in Senseera’s journey to transform diagnostics for liver diseases and beyond, and to accelerate drug development,” said Dr. Ronen Sadeh, CEO of Senseera. “With the support from Lightspeed and our investors, we will advance clinical trials, strengthen collaborations with global pharma leaders, and expand our pipeline to improve patient outcomes.”

About Senseera
Senseera is a next-generation liquid biopsy company pioneering chromatin epigenomics to deliver deeper disease insights. Its GEM BIOMARKERS™ platform enables non-invasive detection and monitoring of diseases, advancing personalized medicine through cutting-edge science and robust molecular analysis.

Contact: [email protected]

Logo – https://mma.prnewswire.com/media/2591678/Senseera.jpg
Logo – https://mma.prnewswire.com/media/2591679/Lightspeed.jpg

SOURCE Senseera

HOUSTON, Jan. 6, 2025 — Cemex is proud to announce its participation in multiple government-sponsored sustainability initiatives, securing funding from state and federal programs to deploy several lower-emission vehicles across its U.S. footprint. This remarkable investment is a crucial step in the company’s ongoing efforts to decarbonize its operations.

Through the Texas Emissions Reduction Plan (TERP), Cemex was awarded approximately $13 million to obtain four lower-emission locomotives and two haul trucks for its cement and aggregate sites in New Braunfels and Katy, Texas. The TERP program provides financial incentives to eligible individuals, businesses, or local governments to reduce emissions from polluting vehicles and equipment. Three of the four new locomotives and both haul trucks entered service in late 2023 and mid-2024 in New Braunfels, respectively.

Looking ahead, Cemex will continue its commitment to protecting air quality by deploying additional equipment in 2025. A $2 million grant from the U.S. Environmental Protection Agency’s (EPA) Diesel Emissions Reduction Act (DERA) Program will allow for two lower-emission locomotives to enter Cemex’s service in Jacksonville and Miami in summer 2025.

“Through these state and federal programs, significant strides toward advancing responsible business practices are more attainable,” said Cemex U.S. President Jaime Muguiro. “Our new lower-emission vehicles play a key role in the development of building materials for roads, schools, hospitals, and more, while also pivotal to our CO2 reduction roadmap.”

Upon placing these emissions-reducing vehicles into service, Cemex decommissions the conventional vehicles they replaced, meeting a core requirement of the programs and reinforcing Cemex’s commitment to a more sustainable future.

This initiative continues Cemex’s efforts at other locations, particularly in Victorville, California, where multiple lower-emission locomotives were added to the fleet. In 2022, nearly 40 low-emission natural gas trucks were introduced to the Southern California fleet, replacing an equal number of older, diesel-powered vehicles. Additionally, in 2023, another lower-emission locomotive was put into service, supported by a $2.5 million grant from the EPA’s Targeted Airshed Grants (TAG) Program.

Decarbonizing its operations is a fundamental aspect of Cemex’s Future in Action program, which focuses on achieving sustainable excellence through climate action, circularity, and natural resource management with the primary objective of becoming a net-zero CO2 company by 2050.

About Cemex U.S.

Cemex is a global building materials company that provides high-quality products and reliable services with a rich history of improving the wellbeing of those it serves through innovative building solutions, efficiency advancements and sustainability efforts. Its U.S. network includes 8 cement plants, close to 50 strategically located cement terminals, nearly 50 aggregate quarries and more than 280 ready-mix concrete plants. Cemex U.S. has been repeatedly recognized for its efforts in sustainability and energy management, including earning U.S. EPA ENERGY STAR® Partner of the Year consecutively since 2019.

SOURCE Cemex USA

Investment will Fuel Renais Gin’s Expansion into North America and Elevate its Position in the Premium Spirits Market

CHICAGO, Jan. 6, 2025 — InvestBev, a leading private equity firm focused exclusively on the adult beverage industry, is excited to announce its significant equity investment in Renais, a rising premium spirits brand based in the United Kingdom. This investment aligns with InvestBev’s ongoing strategy to support innovative brands in the international spirits market, and further strengthens its portfolio within the high-growth gin category.

Renais—renowned for its meticulously crafted gin made from local botanicals and water sourced directly from the renowned winemaking regions in France—has quickly gained acclaim in the UK and European markets. The partnership with InvestBev will accelerate Renais’ expansion efforts, with plans to increase production capacity, extend distribution into North America, and launch a series of marketing campaigns designed to bring its unique offerings to a broader audience.

“We are thrilled to support Renais in its journey to become a globally recognized brand,” said Brian Rosen, General Partner at InvestBev. “The premium gin category continues to demonstrate remarkable potential, and Renais’ quality and innovative approach align perfectly with our strategic investment focus. We believe our capital—coupled with our deep industry expertise and network—will amplify Renais’ ability to reach new consumers and markets.”

InvestBev’s participation will also provide Renais with access to operational guidance and market insights that are critical for rapid growth in the competitive global spirits markets. With this support, Renais aims to bolster its brand presence while maintaining the craftsmanship and quality that sets this brand apart.

“This is an exciting milestone for Renais as we accelerate our growth strategy. We’ll be investing in talent and strategic hires to expand our market presence, capitalizing on the momentum from our launches in California and New York this year,” said Alex Watson, Co-founder and CEO of Renais. “While the gin market has traditionally been led by heritage brands, gin is gaining traction in the states, driven by customer preference for premiumization and the emerging ethos of ‘drink less, but better.’ With this injection of funds, Renais is poised to continue transforming the industry with our ambitious team, innovative distillation process, best-in-class content, and community engagement.”

This partnership continues InvestBev’s record of supporting brands that prioritize authenticity and innovation. InvestBev remains committed to fostering growth across all segments of the adult beverage industry, as demonstrated by its track record of successful partnerships with leading and emerging brands alike.

For more information about InvestBev’s investment in Renais, or to learn more about the firm’s portfolio and services, please visit: https://www.investbev.com/.

About Renais

Renais, a luxury modern gin co-founded by Alex and Emma Watson, is inspired by the beauty of French winemaking traditions and made possible by the rich combined efforts of distillers, artisans, and tastemakers working harmoniously across the United Kingdom and France. The Watson family’s rich winemaking history, which began three decades ago when award-winning winemaker and “Pilier” Chris Watson planted their vineyard Domaine Watson in Chablis, informs Renais’ commitment to craftsmanship and legacy.

Conscientiously distilled from upcycled Grand Cru grapes and tastefully married with all-natural botanicals, Renais Gin is equally as complex as it is silky smooth – proudly made for enjoying neat or mixing, shaking & stirring down into your favorite cocktails or with soda. A Certified B Corporation, Renais launched in the UK in May 2023, and has since established itself in the United States (2024), French, Italian, German, and Australian markets. For more information and where to purchase, visit www.renais.com and follow @renaisgin.

About InvestBev

Founded in 2015 by Brian Rosen, InvestBev Group is a premier private equity firm in the adult beverage industry, known for its short return windows and non-correlated investment strategy. Helmed by 3rd generation industry veteran Brian Rosen, InvestBev Group has raised nearly $200 million across four funds, a $100 million credit platform, and a low-cost insurance provider to distilleries. InvestBev is dedicated to supporting emerging brands and segments within the alcohol sector. Learn more: Website | LinkedIn

Press Contact:

Shannon Duer
845-548-1211

SOURCE InvestBev